Charles Theuer | President and CEO |
Patricia Bitar | Chief Financial Officer |
Tom Shrader | Stifel Nicolaus |
Chad Messer | Needham & Company |
Bert Hazlett | BTIG |
Good day, ladies and gentlemen, and welcome to the TRACON Pharmaceuticals Third Quarter 2017 Earnings Conference Call. At this time, all callers are in a listen-only mode. After the speakers’ prepared remarks, we will conduct a question-and-answer session and instructions will be given at that time.
During today’s call, we will be making certain forward-looking statements, including statements regarding expected timing of clinical trials and results, regulatory activities, future expenses and cash runway, and our development plans and strategy. These statements are subject to various risks that are described in our filings made with Securities and Exchange Commission, including our annual report on Form 10-K for the year ended December 31, 2016, and subsequent quarterly reports on Form 10-Q.